Streck-T-Pack is specially designed for use on Coulter® Counter T Series instruments. Each convenient pack includes diluent, lysing agent and enzymatic cleanser. The shelf life is 18 months from
Streck-ONYX-Pack is specially designed for use on Coulter® ONYX Series instruments. Each pack contains diluent and lysing agent. The shelf life is one year from date of manufacture.
A lytic reagent manufactured for the simultaneous quantitative determination of hemoglobin and white blood cells. Streck-Lysing Agent IIIA is manufactured specifically for use on the Abbott CELL-DYN&
A concentrated enzymatic cleanser manufactured for automated and semi-automated hematology instruments. It is for use on all Abbott CELL-DYN® hematology analyzers, non-differential and differenti
Medicine Products:(Date:5/13/2008)... at high-risk of developing breast cancer, breast ...re cancers than mammography alone, according to re...hwestern Medical Center researchers. , Overall, ... Of those cases, a dozen lesions were suspicious o...h ultrasound and mammography. , The most recen...
(Date:5/13/2008)...y] Adding a screening ultrasound examination to r...n mammography alone, according to results of a maj...und that adding an ultrasound exam also increases ...y biopsies. , Results of the clinical trial, con...g Network (ACRIN) and analyzed by Brown University...
(Date:5/13/2008)...wire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: VRUS... 5th Annual,Global Healthcare Conference being hel...aza Hotel in Monte Carlo, Monaco. Schaefer Price,... an overview of the,company on Tuesday, May 20, 20...cess a simultaneous webcast of Mr. Price,s overvie...
(Date:5/13/2008)...CRME TSX: COM, VANCOUVER, May 13 /PRNewswire-Firs...: COM) today reported financial results for the fi...specified otherwise, are,expressed in Canadian dol...epted Accounting Principles (Canadian GAAP). At cl...te was CAD$1.00=US$0.9742., Results of Operations...
Breaking Medicine News(10 mins):Health News:UT Southwestern researcher: Supplemental breast ultrasound boosts cancer detection 2Health News:Adding ultrasound screening to mammography brings benefits, risks 2Health News:Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th 2Health News:Cardiome Reports First Quarter Results 2Health News:Cardiome Reports First Quarter Results 3Health News:Cardiome Reports First Quarter Results 4Health News:Cardiome Reports First Quarter Results 5(Date:5/12/2008)...SCO, Calif., May 12 /- Napo...unces that it presented a,poster in collaboration ...t,of a patient reported outcomes questionnaire foc...) aspects of chronic diarrhea in persons living wi...Pharmacoeconomics and,Outcomes Research (ISPOR) An...
(Date:5/12/2008)... /PRNewswire-USNewswire/ -- The Alliance for Lupus... of a resolution,supporting the goals and ideals o...y on Mother,s Day. The resolution, introduced by S...ME) calls on all Americans to take the,week of May...selves on,women,s health issues, and recognizes th...
(Date:5/12/2008)...sing neurological recovery in severely-injured, ac...ated with Cethrin, HOPKINTON, Mass., May 12 /PRNe... (Nasdaq: ALSE ) today announced 12-month interim...in, a proprietary recombinant,protein that is bein...and,sensory function after spinal cord injury, or ...
(Date:5/12/2008).../- CryoLife, Inc. (NYSE: C...ocessing company, today announced,the first implan...heart,valve in a patient at the Cleveland Clinic. ...diac surgeon with the Heart and Vascular Institute...cess the combination aortic-mitral human heart,val...
Breaking Medicine Technology:Napo Presents at ISPOR Meeting in Toronto 2Lupus Under the Spotlight: U.S. Congress Shows Support for Women's Health Issues 2Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 2Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 3Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 4Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 5CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic 2CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic 3Manor Care To Vigorously Contest TRO 8681 1Manor Care To Vigorously Contest TRO 8681 2Kaiser Permanente Group Health Study Shows Depression Worsens HIV Treatment 1110 1Kaiser Permanente Group Health Study Shows Depression Worsens HIV Treatment 1110 2Kaiser Permanente Group Health Study Shows Depression Worsens HIV Treatment 1110 32008 Presidential Hopefuls Fail to Respond to Questions About Obesity in U S 8677 12008 Presidential Hopefuls Fail to Respond to Questions About Obesity in U S 8677 2URAC Calls for Comments on Changes to Standards for Health Web Site HIPAA Privacy and Security Accreditation Programs 8673 1URAC Calls for Comments on Changes to Standards for Health Web Site HIPAA Privacy and Security Accreditation Programs 8673 2... BETHESDA, Md., March 26, 2007--Having a build-up... risk of heart attacks and,death from heart diseas...ings from the Multi-Ethnic Study of Atherosclerosi...lood Institute of the,National Institutes of Healt...nary artery calcium is linked to greater risk of,h...
... MINNEAPOLIS--(BUSINESS WIRE)--Mar 26, 2007 - Two-...R III trial confirm the positive,clinical profile ...,bring to nearly 1,300 the number of Endeavor pati...nificantly, among those 1,300,Endeavor patients, t...ombosis using the independent, pre-specified clini...
Other Medicine Technology:Calcium Plaque Build-up in the Arteries Leads to Coronary Heart,Disease in Multi-Ethnic Groups 2Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile 2Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile 3